Growth Capitalist (https://growthcapitalist.com/tag/biomed/page/26/)
Unilife Corp. (UNIS) announced that it has secured up to $45 million in an ATM (At the Market) transaction. The purchase price is the prevailing market price at the time of the Draw Down Notice. Cantor Fitzgerald & Company acted as the exclusive agent on the transaction. Placement Agent counsel was Reed Smith, and issuer counsel was Sichenzia Ross Friedman Ference. See the PlacementTracker Deal Summary.
Antares Pharma (ATRS) announced that it has raised $50 million in a CMPO/Overnight transaction. The common stock was sold at $4.00 per share, an approximate 9% discount to the market price ($4.40) of ATRS at deal announcement. Jefferies & Company and Oppenheimer & Co. acted as co-lead agents, and Cowen and Company and Ladenburg Thalmann & Co. acted as co-agents on the transaction. Placement Agent counsel was Covington & Burling, and issuer counsel was Morgan, Lewis & Bockius. The transaction is expected to close by Oct.
Novavax (NVAX) announced that it has secured up to $50 million in an ATM (At the Market) transaction with MLV & Co. The purchase price is the prevailing market price at the time of the Draw Down Notice. Placement Agent counsel was Bryan Cave, and issuer counsel was Ropes & Gray. An agreement was reached Oct. 1, 2012.
Prana Biotechnology Limited (PRAN) announced that it has raised $6.24 million in a Common Stock transaction. The common stock was sold at $0.19 per share, an approximate 15% discount to the market price ($0.23) of PRAN at deal announcement. JM Financial Group Limited acted as the exclusive agent on the transaction, and the investors were not disclosed. See the PlacementTracker Deal Summary.
